The Russian Ministry of Industry and Trade is developing an additional support mechanism for the pharmaceutical industry, the head of the department, Anton Alikhanov, told RIA Novosti.
“The mechanism under development provides for compensation of costs associated with conducting the final phase of clinical trials of original medicinal preparations,” Alikhanov said, stressing that priority will be given to companies that have developed a “truly new molecule.”
The official also noted that domestic pharmaceutical companies are not lagging behind global manufacturers in this regard. As an example, Alikhanov cited Vladimir-based Generium, which in October registered the innovative drug Clotilia (verenafusp alfa) for the treatment of mucopolysaccharidosis type II (Hunter syndrome). The drug penetrates the blood-nerve barrier to improve the neurological condition, while other drugs can only combat the somatic manifestations of the disease.
“The drug’s production is localized in Russia, including the full cycle,” Alikhanov said.
